The synthesis, hybridization properties and antisense activities of oligodeoxynucleotides (ODNs) containing 7-(1-propynyl)-7-deaza-2′-deoxyguanosine (pdG) and 7-(1-propynyl)-7-deaza-2′-deoxyadenosine (pdA) are described. The suitably protected nucleosides were synthesized and incorporated into ODNs. Thermal denaturation (T m ) of these ODNs hybridized to RNA demonstrates an increased stability relative to 7-unsubstituted deazapurine and unmodified ODN controls. Antisense inhibition by these ODNs was determined in a controlled microinjection assay and the results demonstrate that an ODN containing pdG is ∼6 times more active than the unmodified ODN. 7-Propyne-7-deaza-2′-deoxyguanosine is a promising lead analog for the development of antisense ODNs with increased potency.
INTRODUCTION
Phosphorothioate oligodeoxynucleotides (ODNs) containing the C-5 propyne-modified pyrimidine nucleosides 5-(1-propynyl)-2′-deoxyuridine (pdU) and 5-(1-propynyl)-2′-deoxycytidine (pdC) show high binding affinities for single-strand RNA (1) and significantly enhance the antisense activity of these ODNs (2) . The increased potency of these ODNs is the result of a decreased rate of intracellular dissociation of the double helix and is believed to be mediated by RNase H (3). The increased potency observed with ODNs containing C-5 propyne-modified pyrimidine nucleosides prompted us to explore the use of a similar propyne modification with purine nucleosides.
7-Deaza-2′-deoxyadenosine (7-deaza-dA) and 7-deaza-2′-deoxyguanosine (7-deaza-dG) are known nucleosides in which the 7-nitrogen is replaced by C-H (4-7). Seela and co-workers have incorporated these nucleosides into ODNs and studied their binding affinity towards DNA (8) (9) (10) (11) (12) . Recently, a number of 7-deaza-2′-deoxypurines substituted at the 7-position with either a halogen or a methyl group were incorporated into ODNs and their binding affinity towards DNA determined (13, 14) . The results indicate that 7-substituted deazapurines can increase the binding affinity of ODNs for DNA, but no studies have been carried out against RNA of a mixed sequence. ODNs containing unsubstituted 7-deaza-dG and 7-deaza-2′-deoxyxanthosine have been used in the context of triple helix recognition (15) and 7-alkynylamino-deazapurine nucleosides have also been synthesized and used as flourescent chain terminators in DNA sequencing (16) (17) (18) .
Molecular modeling studies suggested that a propyne attached at the 7-position of 7-deaza-dG and 7-deaza-dA occupies space similar to the propyne in pdU and pdC upon formation of a DNA/RNA double helix. We have synthesized the appropriately protected 7-deazapurine nucleosides 1-4 ( Fig. 1 ) and incorporated these analogs into ODNs. The T m of the DNA/RNA double helix and the antisense activities of these ODNs were then determined. Incorporation of propyne-modified nucleosides 1 and 2 into ODNs significantly enhances the stability of the double helix with single-strand RNA. The ODN containing 7-propynyl -2′-deoxyguanosine (pdG) also leads to enhanced antisense potency in a microinjection assay.
MATERIALS AND METHODS

General procedures
Propyne gas was purchased from Farchan Laboratories (Gainesville, FL) and all other reagents were purchased from Aldrich Chemical Co. 1 H and 31 P NMR spectra were recorded using a General Electric QE 300 spectrophotomer. Exact masses were determined from high resolution FAB mass spectra on a VG Analytical ZAB2-EQ spectrometer (Mass Spectrometry Laboratory, University of California, Berkeley, CA).
Nucleoside synthesis
Pyrrolopyrimidines 5 and 6 (4,5) were used to prepare nucleosides 8 and 9 by the sodium salt glycosylation method (6, 7) . Subsequent alkynylation (16, 17) and protection led to nucleosides 17 and 22. [2,3-d] pyrimidine (10) . To a solution of 15.0 g (27.2 mmol) 8 (6) in 810 ml anhydrous DMF was added 44.4 g (197 mmol) N-iodosuccinimide (NIS), the mixture was heated at 96_C for 6 h and cooled to room temperature. After addition of 4 ml 10% aqeous NaHCO 3 the mixture was concentrated to ∼150 ml, diluted with 300 ml ethyl acetate (EtOAc), washed with H 2 O, 5% aqeous sodium hydrosulfite (Na 2 S 2 O 4 ), saturated NaCl, dried over Na 2 SO 4 and evaporated. The residue was purified by silica gel chromatography using 75-100% CH 2 [2,3-d] pyrimidin-4-one (11) . To a solution of 7.13 g (10.5 mmol) 10 in 106 ml DMF and 72 ml dioxane was added 6.47 g (53.0 mmol) syn-2-pyridinealdoxime and 7.22 ml (57.5 mmol) 1,1,3,3-tetramethylguanidine. The mixture was stirred at room temperature for 24 h and concentrated. The residue was taken up in 400 ml CH 2 Cl 2 , washed with 0.1 M aqeous citric acid (2 × 250 ml), H 2 O (250 ml), saturated aqueous NaHCO 3 (250 ml), dried (Na 2 SO 4 ) and evaporated. The residue was purified by silica gel chromatography using 0-10% EtOAc in CH 2 Cl 2 to afford 6.60 g (95.1% yield) 11. 1 [2,3-d] pyrimidin-4-one (13) . To 6.60 g (10.0 mmol) 11 in 275 ml CH 2 Cl 2 at 0_C was added 4.29 g (∼13.6 mmol) 3-chloroperoxybenzoic acid (MCPBA, 50-60%). After 15 min the ice bath was removed and stirring continued for an additional 105 min. The reaction mixture was diluted with CH 2 Cl 2 , washed with saturated aqueous NaHCO 3 and dried (Na 2 SO 4 ). After removal of Na 2 SO 4 by filtration, MeOH was added to the filtrate to make the solution 4% MeOH. This solution was directly chromatographed through a short column of silica gel, eluted with 4% MeOH in CH 2 Cl 2 and concentrated. The sulfoxide 12 was suspended in 120 ml dioxane, transferred to a Parr Bomb (stainless steel) and saturated with anhydrous ammonia (NH 3 ) at 0_C. The reaction vessel was sealed, heated at 145_C for 8.5 h, cooled and concentrated. The residue was taken up in CH 2 Cl 2 , extracted with saturated aqueous NaHCO 3 , dried (Na 2 SO 4 ) and evaporated. Silica gel chromatography using 5% MeOH in CH 2 Cl 2 yielded 6.0 g impure 13. 1 [2,3-d] pyrimidin-4-one (14) . A suspension of 6.0 g 13 (from the previous reaction) in 120 ml saturated NH 3 /MeOH was heated in a Parr bomb at 140_C for 2 h, cooled and concentrated. The residue was taken up in H 2 O, washed twice with diethyl ether (Et 2 O), filtered (to remove solid impurities) and concentrated to a solid. The solid was briefly heated (with a heat gun for <1 min) in 15 ml H 2 O, cooled for 2 h at 10_C, collected by filtration and washed with cold H 2 O and finally Et 2 O. After drying in a vacuum dessicator, 2.61 g (67% yield from 11) 14 was obtained. 1 
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A mixture of 2.60 g (6.63 mmol) 14, 612 mg (0.53 mmol) tetrakis(triphenylphosphine)palladium(0) [(Ph 3 P) 4 Pd(0)], 202 mg (1.06 mmol) CuI and 1.85 ml (13.3 mmol) triethylamine (TEA) in 22 ml DMF was saturated with propyne at -5_C. The reaction vessel was sealed, sonicated briefly and stirred at room temperature. After 22 h, TLC (NH 4 OH/H 2 O/CH 3 CN, 1:5:94) showed that the reaction was incomplete and [(Ph 3 ) 4 Pd(0)] (612 mg), CuI (202 mg), TEA (1.85 ml) and propyne (-5_C) were added. After stirring for an additional 19 h, MeOH (22 ml), CH 2 Cl 2 (22 ml), Dowex 1 X 8-100 (HCO 3 -form, 2.35 g) and Chelex-100 (sodium form, 607 mg; BioRad) were added. After stirring for 40 min the resins were removed by filtration and washed with MeOH. The combined filtrates were concentrated to a solid, 200 ml CH 2 Cl 2 was added and the mixture sonicated and cooled for 2 h at -20_C. The solid product was removed by filtration, washed with Et 2 O and dried by vacuum dessication to yield 2.11 g impure 15 that was used directly in the next reaction. Silica gel chromatography of a small sample using 0-15% MeOH in CH 2 (16) . To a mixture of 1.95 g (6.41 mmol) 15 in 22 ml DMF was added 0.22 ml absolute EtOH and 1.21 ml (7.06 mmol) N,N-dimethylformamide diethylacetal. After stirring for 24 h at room temperature H 2 O (0.64 ml) was added and the reaction mixture was concentrated to an oil. The crude 16 was used directly in the next reaction. (17) . Crude 16 (∼6.4 mmol) was evaporated from anhydrous pyridine (2×), taken up in 32 ml pyridine and 2.39 g (7.05 mmol) 4,4′-dimethoxytritylchloride (DMT-Cl) was added with stirring. After 18 h, MeOH (2 ml) was added and the mixture concentrated to an oil (∼10 ml). The oil was dissolved in CH 2 Cl 2 , washed with saturated aqueous NaHCO 3 (2×), dried (Na 2 SO 4 ) and evaporated. Silica gel chromatography using 0-10% MeOH in EtOAc afforded 1.25 g (30% yield from 14) 17. 1 (1) 31 P NMR (0.5% TEA in CDCl 3 ) δ 3.71 (dd, 1 J P,H = 616 Hz, 3 J P,H = 9.2 Hz). [2,3- 3 J P,H = 9.6 Hz). [2,3-d] pyrimidine (18) . To a solution of 6.1 g (12 mmol) 9 (6) in 300 ml CH 2 Cl 2 was added 5.1 g (48 mmol) sodium carbonate (Na 2 CO 3 ) and 3.9 g (24 mmol) iodine monochloride (ICl) [2,3-d] pyrimidine (19) . A mixture of 6.7 g (10.6 mmol) 18 in 100 ml 2 M NH 3 /MeOH was heated in a Parr bomb at 150_C for 24 h, cooled and concentrated. The residue was dissolved in hot 
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7-[2-Deoxy-5-O-(4,4′-dimethoxytrityl)-β-D-erythro-pentofuranosyl]-4-(N,N-dibenzoylamino)-5-(1-propynyl)pyrrolo[2,3-d]pyrimidine 3′-(triethylammonium phosphonate) (2).
7-[2-Deoxy-5-O-(4,4′-dimethoxytrityl)-β-D-erythro-pentofuranosyl]-4-{[(N-piperidinyl)methylidene]amino}pyrrolo[2,3-d]pyrimidine 3′-(triethylammonium phosphonate) (4).
Synthesis, purification and T m analysis of oligodeoxynucleotides
All ODNs were synthezised on a Milligen-Biosearch 8750 using the H-phosphonate method and converted to phosphorothioate linkage via S 8 oxidation (19) . The ODNs were purified by PAGE and desalted using a NAP-25 column. T m measurements were obtained at 280 nm in 140 mM KCl/5 mM Na 2 HPO 4 at pH 7.2 as previously described (1). 7-Deaza-2′-deoxyguanosine analogs were incorporated into ODNs of the sequence 5′-GUG-GCU-GGG-CUG-UUC-3′; these ODNs are complementary to the RNA sequence 5′-GAA-CAG-CCC-AGC-CAC-3′ in the SV40 T Antigen (TAg) coding region (Table 1) . 7-Deaza-dA analogs were incorporated into ODNs of the sequence 5′-UCA-UCA-GAG-GAA-UAU-UCC-3′; these ODNs are complementary to the RNA sequence 5′-GGA-AUA-UUC-CUC-UGA-UGA-3′ in the TAg coding region ( Table 1 ). The following extinction coefficients (Σ 260 ) were used to calculate the Σ 260 of the ODNs: dA (15 200), dG (11 800), pdU (3200), pdC (5000), pdG (10 500), pdA (7300), 7-deaza-dG (10 000) and 7-deaza-dA (10 600).
Antisense assays
Microinjection, immunofluorescence staining and fluorescence microscopy were carried out as described (2, 3) . Antisense inhibition was determined by co-microinjection of two expression plasmids (SV40 TAg, derived from p5080, and Escherichia coli Scheme 2.
β-galactosidase, pRSVZ) and ODN into CV1 cells (2,3). The cells were incubated for 4.5 h at 37_C, fixed, immunolabeled and scored visually by fluorescence microscopy for TAg and β-galactosidase expression. Each experiment was repeated in triplicate and IC 50 values are ±5%. Inhibition of TAg was gene specific (no inhibition of β-galactosidase) at concentrations up to 5 µM.
RESULTS AND DISCUSSION
Nucleoside synthesis
The deazaguanosine analog was prepared from 4-chloro-7-(2- (8) , which was in turn prepared by sodium salt glycosylation of 4-chloro-2-(methylthio)pyrrolo [2,3- 
erythro-pentofuranose (7; Scheme 1). Iodination of 8 with NIS afforded iodonucleoside 10 in >90% yield (Scheme 1). A novel hydrolysis of 10 was effected using syn-2-pyridine aldoxime and 1,1,3,3-tetramethylguanidine in a mixture of dioxane and DMF at room temperature to produce 11 in 95% yield. syn-2-Pyridine aldoxime has been used to deliver a hydroxyl group with displacement of a leaving group during deprotection of oligodeoxynucleotide phosphotriesters (21, 22) and in the preparation of uridine analogs (23), but we believe that this is the first example of its use in the synthesis of guanosine analogs. The methylthio group of 11 was converted to the amino group by oxidation and subsequent displacement with NH 3 in dioxane to give 13. Chromatography of 13 through a short column of silica gel was required to remove polar impurities and subsequently aided in the isolation of pure intermediates. The toluoyl protecting groups were removed (NH 3 /methanol) and nucleoside 14 was isolated as a precipitate in 67% overall yield from 11. The two step process of displacement with NH 3 in dioxane followed by deprotection with NH 3 in methanol (MeOH) was necessary, as heating sulfoxide 12 with NH 3 in MeOH resulted in removal of the toluoyls and no displacement of the sulfoxide. Introduction of the propyne using the method of Hobbs (17) afforded 7-(1-propynyl)-7-deaza-2′-deoxyguanosine (pdG, 15). Protection of the exocyclic amino group as the dimethylformamidine (24, 25) followed by 5′-dimethoxytritylation and phosphitylation (19) afforded the hydrogen phosphonate 1. The properly protected 7-deaza-dG hydrogen phosphonate 3 was prepared from 8 in a similar fashion. The deazaadenosine analog was prepared from 4-chloro-7-(2- (9) , which in turn was prepared by sodium salt glycosylation of 4-chloropyrrolo [2,3-d] pyrimidine (6) with chlorosugar 7 (Scheme 1). Iodination of 9 with ICl in CH 2 Cl 2 afforded iodonucleoside 18 in 88% isolated yield (Scheme 2). One step amination and deprotection of 18 with NH 3 in MeOH afforded 7-iodo-7-deaza-2′-deoxyadenosine (19) in 70% yield, which was propynylated to give 7-(1-propynyl)-7-deaza-2′-deoxyadenosine (pdA, 20). Conversion of the exocyclic amino group to the N,N-dibenzoylamide (26, 27) , protection of the 5′-hydroxyl with DMT-Cl and phosphitylation afforded the hydrogen phosphonate 2. The 7-deaza-dA hydrogen phosphonate 4 was prepared in a similar fashion, except that the exocyclic amino group was protected with the N-piperidinyl-methylidene group (24) .
Deazapurine oligodeoxynucleotides
These nucleoside analogs were incorporated into two separate ODN sequences, the 2′-deoxyguanosine analogs were incorporated into a 15mer and the 2′-deoxyadenosine analogs were incorporated into an 18mer (Table 1) , both sequences complementary to the coding region of TAg RNA. These ODNs were used to assess both binding affinity and antisense activity, therefore, the nuclease-stable phosphorothioate and the high affinity pdU and pdC modifications were used for all ODNs.
Biochemical characterization of modified oligodeoxynucleotides
The binding affinity of the phosphorothioate ODNs containing the 7-deazapurine analogs to the complementary RNA strand, as measured by thermal denaturation (T m ), are shown in Table 1 . The results demonstrate that the 7-propynyl analogs bind with higher affinity to RNA than the control purines. Both the deoxyadenosine and deoxyguanosine derivative increased the T m by 0.8_C/substitution relative to the control ODNs. The increase in binding affinity is likely due to increased stacking interactions leading to more favorable enthalpy of binding. Previous studies with 7-substituted deazaadenosine analogs have shown that substitution leads to a more unfavorable entropy of binding that can then be compensated for by increased enthalpy of binding (13) . The unsubstituted 7-deazapurine analogs bound with lower affinity to RNA than the control; 7-deazaguanosine-substituted ODN led to a decrease in T m of 0.6_C/substitution and 7-deazaadenosine substitution led to a decrease of 0.25_C/substitution. Our results with RNA as the target strand are consistent with previous reports with DNA as the target strand, indicating that there are no stacking interactions to compensate for the more unfavorable entropy of binding (13, 14) .
These phosphorothioate ODNs were also assessed for their ability to inhibit gene expression via an antisense mechanism of action. Both sequences shown in Table 1 are complementary to the coding strand of TAg RNA and are downstream of the start codon. Antisense inhibition of TAg was assessed via a microinjection assay with E.coli β-galactosidase as an internal control. The results shown in Table 1 indicate that the antisense activities of the deoxyguanosine (dG) and deoxyadenosine (dA) analogs follow very different trends. Replacement of the 2′-deoxyguanosines in ODN 23 with 7-deaza-dG (ODN 24) results in a decrease in IC 50 from 1.0 to 0.6 µM (∼2-fold increase in activity) and replacement with 7-propynyl-dG (ODN 25) decreases the IC 50 further to 0.15 µM (∼6-fold increase in activity). Conversely, replacement of the 2′-deoxyadenosines in ODN 26 with 7-deaza-dA (ODN 27) resulted in an increase in the IC 50 from 0.5 to 1.5 µM, while replacement with 7-propynyl-dA (ODN 28) led to complete loss of antisense activity at a concentration of up to 5 µM.
It has been shown that propyne substitution of deoxyuridine and deoxycytidine enhances the antisense activity of phophorothioate ODNs and it was expected that a similar trend would be observed with these purine analogs. 7-propynyl-dG does enhance the antisense activity of ODNs, but 7-propynyl-dA decreases the activity. This effect cannot be explained by binding affinity of the ODNs, as both analogs increase the affinity for the target RNA by the same degree. The reason for this dichotomy, at this time, is unclear. It is possible that sequence context may play a role in the difference in activity of these two purine analogs. Within the sequence used for the dG analogs, five of the seven dGs are adjacent to other dGs and the remaining two dG analogs are adjacent to propynyl pyrimidines. This sequence context should favor stacking interactions between adjacent propynyl groups. Conversely, the sequence used for the dA analogs contains only one AA pair, with three of the six remaining dA analogs adjacent to unmodified dG. This context would minimize favorable stacking interactions. Additionally, there may be a difference in ability to recruit RNase H cleavage of the complementary RNA by the two different ODNs. Continued experimentation will be required to determine if either of these two factors influence the antisense activity of these ODNs or if another unknown variable is at work.
These antisense experiments were carried out by nuclear microinjection of the ODN into cells, due to the lack of cellular permeation observed with phosphorothioate ODNs (2, (28) (29) (30) (31) . It has been shown that ODNs require complexation with cationic lipids to be efficiently delivered to the nuclear compartments of cells (2, (28) (29) (30) (31) (32) . Substitution of the ODNs with 7-propynyl-dG does not enhance cellular uptake of these ODNs, addition of 5 µM ODN to the medium resulting in no antisense inhibition with all ODNs tested (data not shown).
In summary, suitably protected derivatives of 7-propynyl-dG and 7-propynyl-dA have been prepared and incorporated into ODNs. Thermal denaturation of the phosphorothioate ODN/RNA double helix demonstrates that both analogs increase binding affinity relative to unmodified purines. The deoxyguanosine analog dramatically enhances antisense activity of the ODN, whereas the deoxyadenosine derivative decreases the activity of the ODN. The 7-propynyl-2′-deoxyguanosine analog may be a valuable lead for increased biological potency of antisense ODNs.
